Cargando…

Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials

This manuscript reviews the primary and secondary endpoints of pivotal phase III trials with immunomodulatory drugs in multiple sclerosis (MS). Considering the limitations of previous trial designs, we propose new standards for the planning of clinical trials, taking into account latest insights int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gehr, Sinje, Kaiser, Thomas, Kreutz, Reinhold, Ludwig, Wolf-Dieter, Paul, Friedemann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883016/ https://www.ncbi.nlm.nih.gov/pubmed/31832116 http://dx.doi.org/10.1007/s13167-019-00192-z

Ejemplares similares

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
por: Uitdehaag, Bernard M. J.
Publicado: (2018)

Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis
por: Graves, Jennifer S., et al.
Publicado: (2022)

Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial
por: Dörr, Jan, et al.
Publicado: (2018)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Clinical trials in multiple sclerosis: potential future trial designs
por: Manouchehri, Navid, et al.
Publicado: (2019)

Two Stage Designs for Phase III Clinical Trials
por: Follmann, Dean, et al.
Publicado: (2020)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial
por: Dörr, Jan, et al.
Publicado: (2012)

Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care
por: Jalusic, Kris Oliver, et al.
Publicado: (2021)

NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials
por: Hegazi, Omar E., et al.
Publicado: (2023)

Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS)
por: Bäcker-Koduah, Priscilla, et al.
Publicado: (2020)

Enhancing involvement of people with multiple sclerosis in clinical trial design
por: Gray, Emma, et al.
Publicado: (2023)

Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial
por: Rosche, Berit, et al.
Publicado: (2013)

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial
por: Villoslada, Pablo, et al.
Publicado: (2015)

High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial
por: Dörr, Jan, et al.
Publicado: (2020)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020)

Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis)
por: Veauthier, Christian, et al.
Publicado: (2015)

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial
por: Laurent, Sarah A., et al.
Publicado: (2023)

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2016)

A framework for the design and analysis of phase III randomised trials in uncommon diseases
por: Parmar, Mahesh, et al.
Publicado: (2015)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

A randomized controlled phase II trial of riluzole in early multiple sclerosis
por: Waubant, Emmanuelle, et al.
Publicado: (2014)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
por: Pantzaris, Marios C, et al.
Publicado: (2022)

Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
por: Bellmann-Strobl, Judith, et al.
Publicado: (2021)

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)
por: Biglan, Kevin M., et al.
Publicado: (2017)

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2017)

Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis
por: Li, Vivien, et al.
Publicado: (2022)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
por: Schippling, Sven, et al.
Publicado: (2016)

Using meta-analysis of Phase II trials to predict Phase III trial results
por: Burke, Danielle, et al.
Publicado: (2013)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2011)

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials
por: Gärtner, Jutta, et al.
Publicado: (2018)

Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
por: Borrmann, Steffen, et al.
Publicado: (2008)

Using Bayesian adaptive designs to improve phase III trials: a respiratory care example
por: Ryan, Elizabeth G., et al.
Publicado: (2019)

Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
por: Bachy, Emmanuel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_95n6jr3v393ssb79nh8o3evugg